Anthem Blue Cross

Part B Updates for Praluent, Repatha, and Sylvant

Anthem Blue Cross is adding the following three new injectable drugs to the 2016 Medicare Advantage list of Part B Injectables / Infusibles requiring prior authorization. As of 01/01/2016, providers must call for prior authorization of these drugs.

Drugs billed with NOC HCPCS J code (J3490 and J3590)

1. Praluent (alirocumab): used to reduce serum low-density lipoprotein cholesterol (LDL-C) - (unlisted, no J code established at this time)
2. Repatha (evolocumab): used to reduce serum low-density lipoprotein cholesterol (LDL-C) - (unlisted, no J code established at this time)
3. Sylvant (siltuxumab): for treatment of Multicentric Castleman’s disease (MCD) (C9455)

Please note two of these drugs are currently billed under the Not Otherwise Classified J code (J3490 and J3590). Since this code includes all drugs NOC, the plan’s denial will be for the drug, and not the HCPCS.

This update to the 2016 prior authorization requirement applies to all of Anthem’s Medicare Advantage plans.

55856WPSENMUB 09/11/15

Anthem Blue Cross is the trade name of Blue Cross of California: Independent licensee of the Blue Cross Association. ® ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross names and symbols are registered marks of the Blue Cross Association.